Vascular Biogenics (Vascular Biogenics) Net Income From Continuing Operations : $-15.96 Mil (TTM As of Jun. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Vascular Biogenics Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Vascular Biogenics's net income from continuing operations for the three months ended in Jun. 2023 was $-0.87 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Jun. 2023 was $-15.96 Mil.

Vascular Biogenics Net Income From Continuing Operations Historical Data

The historical data trend for Vascular Biogenics's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vascular Biogenics Net Income From Continuing Operations Chart

Vascular Biogenics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Net Income From Continuing Operations

Get a 7-Day Free Trial

-20.50

-19.40

-24.23

-29.92

-32.30

Vascular Biogenics Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Net Income From Continuing Operations	Get a 7-Day Free Trial															-9.43	-9.17	-3.27	-2.64	-0.87

Vascular Biogenics Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-15.96 Mil.

Vascular Biogenics (Vascular Biogenics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vascular Biogenics Ltd (NAS:VBLT) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

N/A

Address

8 HaSatat Street, Modi’in, ISR, 7178106

Website

https://www.vblrx.com

Vascular Biogenics Ltd is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of first-in-class treatments for cancer. The lead product candidate of the company is VB-111 which is a gene-based biologic which is being developed for solid tumor indications for recurrent glioblastoma, an aggressive form of brain cancer. The company is also engaged in conducting a program targeting anti-inflammatory diseases, based on the use of Lecinoxoid platform technology. The product brands of the company include VTS, Vascular Targeting Systems, Vbl, Vascular Biogenics And Vascular Therapeutics.

Executives

Builders Vc Fund I, L.p.	10 percent owner	201 MISSION STREET, SUITE 2350, SAN FRANCISCO CA 94105
James Jimin Kim	10 percent owner	C/O NOTABLE LABS, INC., 320 HATCH DRIVE, FOSTER CITY CA 94404
B Capital Group Management, L.p.	10 percent owner	1240 ROSECRANS AVE., 5TH FLOOR, MANHATTAN BEACH CA 90266
B Capital Group Investors Ii Ltd.	10 percent owner	1240 ROSECRANS AVE., 5TH FLOOR, MANHATTAN BEACH CA 90266
B Capital Group Partners Ii, L.p.	10 percent owner	1240 ROSECRANS AVE., 5TH FLOOR, MANHATTAN BEACH CA 90266
Joseph P Wagner	officer: Chief Scientific Officer	320 HATCH DRIVE, FOSTER CITY CA 94404
Tuomo Patsi	director	320 HATCH DRIVE, FOSTER CITY NY 94404
Thomas Bock	director, officer: Chief Executive Officer	320 HATCH DRIVE, FOSTER CITY NY 94404
Michele Galen	director	320 HATCH DRIVE, FOSTER CITY CA 94404
Fr Capital Holdings, L.p.	10 percent owner	2400 MARKET STREET, SUITE 237, PHILADELPHIA PA 19103
B Capital Fund Ii, L.p.	10 percent owner	C/O B CAPITAL GROUP MANAGEMENT, L.P., 1240 ROSECRANS AVE., 5TH FLOOR, MANHATTAN BEACH CA 90266
Builders Vc Fund I (canada), L.p.	10 percent owner	201 MISSION STREET, SUITE 2350, SAN FRANCISCO CA 94105
Builders Vc Entrepreneurs Fund I, L.p.	10 percent owner	201 MISSION STREET, SUITE 2350, SAN FRANCISCO CA 94105
Dubin Thomas I H	director	C/O ALEXION PHARMACEUTICALS INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Peter Feinberg	director	C/O IMMUNEERING CORPORATION, 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE MA 02142